VC Profile: Jeito Capital in final stretch of biotech fund deployment
At a time when many big-ticket GPs are buying up specialist life science investors, France-based Jeito Capital is focused on staying an independent investor as it gears up to deploy the remaining third of its EUR 534m debut fund, founder Rafaèle Tordjman tells Unquote.
More on GPs
Advent raises USD 25bn for GPE X
Around 40% larger than its predecessor, the new fund was raised in less than six months, managing director Johanna Barr tells Unquote
Sun European acquires DD Group in carve out from IDH
Vendor Palamon said deal is phase one of returning IDH to pureplay dentistry, will invest proceeds in M&A
The Bolt-Ons Digest – 23 May 2022
Unquote’s selection of the latest add-ons featuring Nordic's Advanz, H2's Optegra, Sovereign's Zenitech, Carlyle's Dept, and more
Palatine bolsters impact and buyout teams
Rupert Brown moves to the impact team after promotion; Carly Sinicrope joins from Clearwater as investment manager
Latest News
Raise heads for second close for debut impact VC fund
French sponsor seeks to attract state-backed LPs for new strategy targeting ESG-focused startups
Graphite makes value creation and investment team hires
Director appointments include Rutland Partners' Matt Hamilton-Allen, who joins the investment team
Pantheon closes private debt secondary fund on USD 834m
New vehicle exceeded target by more than USD 300m; aims for up to 20% exposure to European debt
Cathay Capital launches EUR 500m health fund
New vehicle will invest at the crossover of health care, life sciences and tech with EUR 5m-50m tickets